News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

September 24, 2020 Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit
September 21, 2020 Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020
September 15, 2020 Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH
September 2, 2020 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
July 31, 2020 Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results
July 7, 2020 Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
July 2, 2020 Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
June 16, 2020 Apellis Pharmaceuticals to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
June 12, 2020 New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH
June 10, 2020 Apellis Announces Investor Conference Call to Discuss Phase 3 PEGASUS Data to be Presented at the 25th Annual Congress of the European Hematology Association (EHA)